Terms: = Prostate cancer AND NSD1, FLJ44628, 64324, ENSG00000165671, Q96L73, FLJ22263, DKFZp666C163, ARA267, STO, SOTOS
11 results:
1. The role of nsd1, NSD2, and NSD3 histone methyltransferases in solid tumors.
Topchu I; Pangeni RP; Bychkov I; Miller SA; Izumchenko E; Yu J; Golemis E; Karanicolas J; Boumber Y
Cell Mol Life Sci; 2022 May; 79(6):285. PubMed ID: 35532818
[TBL] [Abstract] [Full Text] [Related]
2. The Silent Operation Theatre Optimisation System (sotos
Leitsmann C; Uhlig A; Popeneciu IV; Boos M; Ahyai SA; Schmid M; Wachter R; Trojan L; Friedrich M
J Robot Surg; 2021 Aug; 15(4):519-527. PubMed ID: 32776286
[TBL] [Abstract] [Full Text] [Related]
3. Lead discovery, chemical optimization, and biological evaluation studies of novel histone methyltransferase SET7 small-molecule inhibitors.
Hou Z; Min W; Zhang R; Niu A; Li Y; Cao L; Han J; Luo C; Yang P; Ding H
Bioorg Med Chem Lett; 2020 May; 30(9):127061. PubMed ID: 32173197
[TBL] [Abstract] [Full Text] [Related]
4. Global and region-specific post-transcriptional and post-translational modifications of bisphenol A in human prostate cancer cells.
Fatma Karaman E; Caglayan M; Sancar-Bas S; Ozal-Coskun C; Arda-Pirincci P; Ozden S
Environ Pollut; 2019 Dec; 255(Pt 2):113318. PubMed ID: 31610501
[TBL] [Abstract] [Full Text] [Related]
5. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract] [Full Text] [Related]
6. Integrated Analysis of Genetic Abnormalities of the Histone Lysine Methyltransferases in prostate cancer.
Zhang Y; Yan L; Yao W; Chen K; Xu H; Ye Z
Med Sci Monit; 2019 Jan; 25():193-239. PubMed ID: 30616239
[TBL] [Abstract] [Full Text] [Related]
7. Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.
Katoh M
Epigenomics; 2016 Feb; 8(2):285-305. PubMed ID: 26411517
[TBL] [Abstract] [Full Text] [Related]
8. CaM kinase control of AKT and LNCaP cell survival.
Schmitt JM; Smith S; Hart B; Fletcher L
J Cell Biochem; 2012 May; 113(5):1514-26. PubMed ID: 22173970
[TBL] [Abstract] [Full Text] [Related]
9. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development.
Bianco-Miotto T; Chiam K; Buchanan G; Jindal S; Day TK; Thomas M; Pickering MA; O'Loughlin MA; Ryan NK; Raymond WA; Horvath LG; Kench JG; Stricker PD; Marshall VR; Sutherland RL; Henshall SM; Gerald WL; Scher HI; Risbridger GP; Clements JA; Butler LM; Tilley WD; Horsfall DJ; Ricciardelli C;
Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2611-22. PubMed ID: 20841388
[TBL] [Abstract] [Full Text] [Related]
10. Identification and characterization of a novel androgen receptor coregulator ara267-alpha in prostate cancer cells.
Wang X; Yeh S; Wu G; Hsu CL; Wang L; Chiang T; Yang Y; Guo Y; Chang C
J Biol Chem; 2001 Nov; 276(44):40417-23. PubMed ID: 11509567
[TBL] [Abstract] [Full Text] [Related]
11. Identification and characterization of androgen receptor associated coregulators in prostate cancer cells.
Sampson ER; Yeh SY; Chang HC; Tsai MY; Wang X; Ting HJ; Chang C
J Biol Regul Homeost Agents; 2001; 15(2):123-9. PubMed ID: 11501969
[TBL] [Abstract] [Full Text] [Related]
